Annals of Hepato-Biliary-Pancreatic Surgery

Indexed in /covered by CAS, KoreaScience & DOI/Crossref:eISSN 2508-5859   pISSN 2508-5778

Table. 5.

Table. 5.

Number of patients in each group in survival analysis

Factors No of patients (%)

1 year 3 year 5 year
Sex
Male 57 (58.76%) 51 (59.30%) 38 (63.33%)
Female 40 (41.24%) 35 (40.70%) 22 (36.67%)
Significant weight loss
Yes 65 (67.71%) 58 (68.23%) 41 (68.33%)
No 31 (32.29%) 27 (31.76%) 19 (31.67%)
DM
Yes 23 (24.21%) 22 (26.19%) 14 (23.33%)
No 72 (75.79%) 62 (73.81%) 46 (76.67%)
New onset DM
Yes 11 (11.34%) 11 (13.09%) 6 (10.00%)
No 86 (88.66%) 73 (86.90%) 54 (90.00%)
Type of Pancreaticoduodenectomy
Pylorus resecting surgery 45 (46.39%) 43 (50.00%) 24 (40.00%)
Pylorus preserving surgery 52 (53.61%) 43 (50.00%) 36 (60.00%)
Site
Pancreas 25 (25.77%) 21 (24.42%) 10 (16.67%)
Bile duct 20 (20.62%) 18 (20.93%) 12 (20.00%)
Ampulla 36 (37.11%) 32 (37.21%) 28 (46.67%)
Duodenum 16 (16.49%) 15 (17.44%) 10 (16.66%)
T stage
T 1 15 (16.48%) 15 (18.29%) 14 (24.14%)
T 2 34 (37.36%) 27 (32.93%) 16 (27.59%)
T 3 39 (42.86%) 37 (45.12%) 25 (43.10%)
T 4 3 (3.29%) 3 (3.66%) 3 (5.17%)
N stage
N 0 54 (62.07%) 47 (60.26%) 35 (64.81%)
N 1 30 (34.48%) 28 (35.89%) 18 (33.33%)
N 2 3 (3.45%) 3 (3.85%) 1 (1.85%)
Tumor differentiation
Well 22 (27.50%) 22 (30.55%) 18 (33.33%)
Moderate 55 (68.75%) 47 (65.28%) 34 (62.96%)
Poor 3 (3.75%) 3 (4.17%) 2 (3.70%)
Resection margin
Negative 83 (92.22%) 75 (92.59%) 52 (91.23%)
Positive 7 (7.78%) 6 (7.41%) 5 (8.77%)
Adjuvant therapy
Yes 50 (53.76%) 45 (53.57%) 36 (62.07%)
No 43 (46.24%) 39 (46.43%) 22 (37.93%)

DM, diabetes mellitus

Ann Hepatobiliary Pancreat Surg 2021;25:230-41 https://doi.org/10.14701/ahbps.2021.25.2.230
© 2021 Ann Hepatobiliary Pancreat Surg